ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,702.55
-0.19%
US Tech 100
19,287.60
-0.24%
Dow Jones
42,063.36
0.09%
Brent Oil
74.135
0.00%
Bitcoin
62,868.82
-0.53%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Arbutus Biopharma Corporation (ABUS) Quote

Arbutus Biopharma Corporation

Arbutus Biopharma Corporation (ABUS)

NASDAQ
4.02
-0.12
(-2.90%)
Closed September 21 4:00PM
Delayed by 15 minutes
4.05
0.03
(0.75%)
After Hours: 6:21PM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
4.05
Bid
4.05
Ask
4.15
Volume
7,464,597
4.015 Day's Range 4.18
1.69 52 Week Range 4.725
Market Cap
764.567M
Previous Close
4.14
Open
4.15
Last Trade
10
@
4.145
Last Trade Time
Financial Volume
$ 30,937,089
VWAP
4.1445
Average Volume (3m)
1,093,026
Shares Outstanding
188,782,029
Dividend Yield
-
PE Ratio
-10.49
Earnings Per Share (EPS)
-0.39
Revenue
18.14M
Net Profit
-72.85M

About Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid na... Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.tekmirapharm.com
Headquarters
Burnaby, British Columbia, Can
Founded
-
Arbutus Biopharma Corporation is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ABUS. The last closing price for Arbutus Biopharma was $4.14. Over the last year, Arbutus Biopharma shares have traded in a share price range of $ 1.69 to $ 4.725.

Arbutus Biopharma currently has 188,782,029 shares outstanding. The market capitalization of Arbutus Biopharma is $781.56 million. Arbutus Biopharma has a price to earnings ratio (PE ratio) of -10.49.

Ask ADVFN Intelligence (AI)

Arbutus Biopharma (ABUS) Options Flow Summary

ABUS Options Flow

Overall Flow

Bullish

Net Premium

27k

Calls / Puts

100.00%

Buys / Sells

0.00%

OTM / ITM

0.00%

Sweeps Ratio

0.00%

ABUS Latest News

More News

Arbutus to Participate in Two Upcoming Investor Conferences

WARMINSTER, Pa., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive...

September 03 2024
GlobeNewswire Inc.

Form S-8 - Securities to be offered to employees in employee benefit plans

August 08 2024
Edgar (US Regulatory)

Form 8-K - Current report

August 05 2024
Edgar (US Regulatory)

Form 8-K - Current report

August 01 2024
Edgar (US Regulatory)

Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update

End-of-treatment data presented at the EASL Congress from two Phase 2a clinical trials supports advancing imdusiran as a potential cornerstone in a HBV functional cure treatment regimen IM-PROVE I...

August 01 2024
GlobeNewswire Inc.

Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update

WARMINSTER, Pa., July 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop...

July 18 2024
GlobeNewswire Inc.

Form 8-K - Current report

June 06 2024
Edgar (US Regulatory)

Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels

Data highlighted in oral presentation at the European Association for the Study of the Liver (EASL) Congress WARMISTER, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation...

June 06 2024
GlobeNewswire Inc.

Form 8-K - Current report

June 05 2024
Edgar (US Regulatory)

Arbutus’ Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure

At the end of treatment, 33.3% of patients receiving imdusiran for 48 weeks, interferon (IFN) for 24 weeks and ongoing nucleoside analogue (NA) therapy achieved undetectable levels of HBsAg that...

June 05 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.29-6.682027649774.344.544.019912579914.20000982CS
40.25.194805194813.854.7253.7913789004.22524074CS
120.9329.80769230773.124.7252.9910930263.84932456CS
261.5662.65060240962.494.7252.311605463.37243029CS
522.07104.5454545451.984.7251.699930882.94408541CS
156-0.15-3.571428571434.26.51.6918182333.5187872CS
2602.4145.4545454551.6590.8121151163.68244673CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BNZIBanzai International Inc
$ 5.645
(96.01%)
61.39M
ZJYLJin Medical International Ltd
$ 3.975
(50.00%)
1.24M
ANEBAnebulo Pharmaceuticals Inc
$ 2.9001
(39.43%)
78.85k
XPONExpion360 Inc
$ 0.081
(39.18%)
1.46B
AENTAlliance Entertainment Holding Corporation
$ 2.74
(34.31%)
4.23M
GSIWGarden Stage Ltd
$ 1.34
(-82.89%)
26.44M
CRBPCorbus Pharmaceuticals Holdings Inc
$ 19.51
(-62.26%)
12.29M
LGCBLinkage Global Inc
$ 0.4183
(-57.70%)
2.16M
BFIBurgerFi International Inc
$ 0.0855
(-42.27%)
15.05M
SKYESkye Bioscience Inc
$ 3.17
(-42.26%)
5.14M
XPONExpion360 Inc
$ 0.081
(39.18%)
1.46B
NVDANVIDIA Corporation
$ 116.00
(-1.59%)
378.16M
AAPLApple Inc
$ 228.20
(-0.29%)
320.24M
INTCIntel Corporation
$ 21.84
(3.31%)
261.68M
VERBVerb Technology Company Inc
$ 0.0742
(33.45%)
178.65M

ABUS Discussion

View Posts
mick mick 11 hours ago
https://www.stockscores.com/charts/charts/?ticker=ABUS
👍️0
mick mick 2 weeks ago
ABUS
Arbutus Biopharma Corporation
4.5488
0.0388 (0.86%)
Volume: 1,579,948
Day Range: 4.39 - 4.56
Last Trade Time: 7:46:00 PM EDT
👍️0
db7 db7 2 weeks ago
breaking out; dare i say 'someone' knows 'something'(?)
👍️0
db7 db7 2 weeks ago
ARBUTUS PHARMA CORP. et al v. PFIZER INC. et al "Please take notice that an in-person Markman Hearing is hereby scheduled for 12/18/2024 at 10:30AM in Trenton- Courtroom 4W. So Ordered by Judge Zahid N. Quraishi on 9/3/2024. (kas)"
👍️0
db7 db7 3 weeks ago
ABUS over $4
👍️0
Monksdream Monksdream 3 weeks ago
ABUS under $4
👍️0
DewDiligence DewDiligence 2 months ago
ABUS pares pipeline–reduces workforce 40%:

https://finance.yahoo.com/news/arbutus-reports-second-quarter-2024-113000099.html

The company’s will focus on clinical development of Imdusiran regimens for HBV, but will terminate research on new HBV compounds.

Oddly (for the reason mentioned at the bottom of #msg-174556022), ABUS opted to retain its oral PD-1 program.
👍️0
Rockurstocks Rockurstocks 2 months ago
Not for long! $ABUS$
👍️0
Monksdream Monksdream 2 months ago
ABUS under $4
👍️0
mick mick 2 months ago
ABUS
Arbutus Biopharma Corporation
3.645
-0.135 (-3.57%)
Volume: 449,700
Day Range: 3.645 - 3.845
Last Trade Time: 2:29:04 PM EDT
👍️0
Monksdream Monksdream 2 months ago
ABUS new 52/week high
👍️0
db7 db7 2 months ago
👍️0
db7 db7 3 months ago
https://www.sec.gov/Archives/edgar/data/1447028/000089542124000390/ArbutusABUS.txt
👍️0
db7 db7 4 months ago
New Presentation: https://investor.arbutusbio.com/static-files/f33bde13-92b8-48c4-a40e-36cf6dd25852
👍️0
db7 db7 4 months ago
Poster for EASL https://www.arbutusbio.com/wp-content/uploads/2024/06/WED-371-Yuen-et-al-AB-729-201-IFN-poster-EASL-2024_FINAL.pdf
👍️0
mick mick 4 months ago
ABUS
Arbutus Biopharma Corporation
3.341
-0.019 (-0.57%)
Volume: 534,638
Day Range: 3.30 - 3.385
Last Trade Time: 12:14:00 PM EDT
Delayed by 15 minutes
👍️0
db7 db7 4 months ago
EASL June 6-8th:
https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-present-imdusiran-data-easl-congress-2024

"
HBsAg = LLOQ (lower limit of quantification) with detectable anti-HBs was observed at end-of-treatment in 28% of subjects who received 4 or 6 doses of imdusiran plus 24 weeks of IFN
"
👍️0
db7 db7 4 months ago
Arbutus is waking up a little following yesterday's Motion to Dismiss with Acuitas:
https://www.law360.com/ip/articles/1839088/judge-tosses-acuitas-covid-biotech-ip-suit-

other important events of late include:

1) company stating they have stopped their ATM and don't see a need to use it the rest of this year

2) the Markman order against Moderna that went in their favor:
https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-biopharma-announces-claim-construction-ruling-its

3) Activist becoming involved:
https://www.morningstar.com/news/business-wire/20240517970994/whitefort-capital-publishes-open-letter-to-arbutus-biopharma-shareholders-outlining-paths-to-maximize-value
👍️0
db7 db7 4 months ago
issue here, now, might be too many open $3 calls? will mm's hold her under....
👍️0
db7 db7 4 months ago
mgmt killed this stock with that ATM; imo, used in a suspicious manner... ie: they put a lid on her on the markman order release at $3ish .. WHY would you do that? They could have raised same money at double the price
👍️0
MWM MWM 4 months ago
Nice!
👍️0
db7 db7 4 months ago
https://www.businesswire.com/news/home/20240517970994/en/
👍️0
db7 db7 4 months ago
from Whitefort's 13D filed today: "The Reporting Persons have conveyed their view to the Issuer’s Board of Directors (the “Board”) that the current market price of the Shares does not reflect the Issuer’s intrinsic value. The Reporting Persons have requested that the Board immediately terminate the Issuer’s ATM program and explore all strategic options for the Issuer’s hepatitis B virus (HBV) portfolio. The Reporting Persons hope to continue to work constructively and collaboratively with the Board on these critical initiatives and intend to actively engage with shareholders and others regarding their views."
👍️0
Monksdream Monksdream 5 months ago
ABUS under $3
👍️0
mick mick 5 months ago
TWTR
Twitter Inc
53.70
0.00 (0.00%)
Volume:
👍️0
Monksdream Monksdream 6 months ago
ABUS new 52 hi
👍️0
db7 db7 6 months ago
looking a little better today; i guess it's going to be slow and steady and not the rocket on markman day like i hoped. i think this is looking really good med-long term on the litigation from after that markman ruling

also, looking forward to EASL in june
👍️0
mick mick 6 months ago
ABUS
Arbutus Biopharma Corporation
3.00
0.08 (2.74%)
Volume: 1,253,240
Day Range: 2.86 - 3.11
Bid: 2.99
Ask: 3.00
Last Trade Time: 9:56:51 AM EDT
Total Trades: 3,890
👍️0
mick mick 6 months ago
ABUS
Arbutus Biopharma Corporation
3.00
0.08 (2.74%)
Volume: 1,253,240
Day Range: 2.86 - 3.11
Bid: 2.99
Ask: 3.00
Last Trade Time: 9:56:51 AM EDT
Total Trades: 3,890
👍️0
mick mick 6 months ago
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
03/05/2024 04:48:49 PM
👍️0
mick mick 6 months ago
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
03/05/2024 04:48:49 PM
👍️0
mick mick 6 months ago
Arbutus to Participate in Two Upcoming Investor Conferences
03/08/2024 07:30:00 AM
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
03/05/2024 04:48:49 PM
👍️0
mick mick 6 months ago
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
04/04/2024 08:30:49 AM
Arbutus to Participate in Two Upcoming Investor Conferences
03/08/2024 07:30:00 AM
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
03/05/2024 04:48:49 PM
👍️0
Paullee Paullee 6 months ago
07:15 AM EDT, 04/04/2024 (MT Newswires) -- A US court ruled against Moderna (MRNA) in a patent infringement case by Arbutus (ABUS) over its COVID-19 vaccines, Reuters reported Wednesday.

US District Judge Mitchell Goldberg interpreted the patents in ways that favored Arbutus' case and hurt Moderna', Reuters reported.

Arbutus sued Moderna in 2022, claiming the company's COVID-19 vaccine impinged on its patents for lipid nanoparticles that shield the vaccine's mRNA from the body's immune system.

Moderna and Arbutus did not immediately respond to MT Newswires' requests for comment.
👍️0
MWM MWM 6 months ago
Watching all 3 stocks. $ABUS is kind of moving...
👍️0
db7 db7 6 months ago
was going to take all '3' to explode imo..
👍️0
MWM MWM 6 months ago
Yes, I'm trying to read it myself
👍️0
db7 db7 6 months ago
decision is out; looks like arbutus won '2' and moderna '1' .. please confirm
👍️0
db7 db7 6 months ago
https://dailycaller.com/2024/03/14/drew-johnson-moderna-covid-vax-patent-infringement-biden-admin/
👍️ 1
Desert dweller Desert dweller 7 months ago
My bad on post a few weeks ago. When I posted about $MRNA cash position, I didn't do the research I should have done and used what was on cash flow statement and didn't look into long term investments, very sloppy of me. Sorry about that.

In today's release, they are projecting to use $4.3 billion of their cash plus investments during 2024. At 12/31/23 they reported cash plus LT investments of $13.3 billion and project about $9 billion at end of 2024. It will take longer than I thought for them to run out of cash and hopefully $ABUS takes a huge chunk of it. Today MRNA had a surprise profit, and I am still hoping that $ABUS finally cleans their clock for their blatant theft of IP.
👍️ 1
Desert dweller Desert dweller 7 months ago
Handle on twitter is @DesertDweller93
👍️0
MWM MWM 7 months ago
Great post!

What’s your handle on Twitter?
👍️0
Desert dweller Desert dweller 7 months ago
I've been saying on X for a month or so that $MRNA will be suffering a drop once it becomes known that they have roughly a year's worth of cash left, I just discovered this recently. They are burning almost $7 billion/year and they will report less than that at 12/31/23. That on top of the fact that during the past 3 years, they spent $7 billion in buybacks at prices much higher than current prices, all the way up to $300+. My prediction is major restructuring or significant secondary very soon. I bet they wish they had that cash now instead of overpriced treasury stock but then mgt wouldn't have been able to sell at those inflated covid prices.

Hope $ABUS puts them into bankruptcy, the f'n thieves and I hope ABUS cleans $PFE and Biontech's clock too. They all know they are stealing the tech and just don't care. About time David kicks Goliath's ass again.
👍️0
MWM MWM 7 months ago
A couple bad headlines for MRNA of late. Here is one of todays...

Moderna’s RSV Vaccine May Lose Efficacy Faster Than GSK and Pfizer’s
👍️0
db7 db7 7 months ago
yes, quite the drop yesterday and today on mrna... g/l!
👍️0
MWM MWM 7 months ago
Puts on $MRNA might be the best play. If they have to pay up to $ABUS I have a feeling it might see a precipitous drop...

MRNA bad news is piling up there...
👍️0
db7 db7 7 months ago
https://twitter.com/themightyforego/status/1755757415750865356?s=46
👍️0
MWM MWM 7 months ago
And also

Get on Twitter Damn it lol!
👍️0
db7 db7 7 months ago
wasn't.. will check it out... thanks!!
👍️0
MWM MWM 7 months ago
Also

Are you watching VKTX?
👍️0

Your Recent History

NASDAQ
ABUS
Arbutus Biopharma
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved